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Abstract 
Equine Mesenchymal stem/stromal cells (MSCs) are multipotent cells that are 
widely used for treatment of musculoskeletal injuries, and there is significant interest 
in expanding their application to non-orthopedic conditions. MSCs possess 
antibacterial and immunomodulatory properties which may be relevant for 
combatting infection, however, comparative studies using MSCs from different origins 
have not been carried out in the horse, and this was the focus of the present study. 
Our results showed that MSC-conditioned media attenuated the growth of Escherichia 
coli, and that this effect was, on average, more pronounced for endometrium (EM)- 
and adipose tissue (AT)- than for bone marrow (BM)-derived MSCs. In addition, the 
antimicrobial Lipocalin-2 was expressed at mean higher levels in EM- compared to AT- 
and BM-MSCs, and the bacterial product lipopolysaccharide (LPS) stimulated its 
production by all three MSC types. We also show that MSCs express IL-6, IL-8, MCP-1, 
CCL5 and TLR4, and that, in general, these cytokines were induced in all cell types by 
LPS. Low expression levels of the macrophage marker CSF1-R were detected in BM- 
and EM-MSCs, but not in AT-MSCs. Altogether, these findings suggest that equine 
MSCs from endometrium, adipose tissue and bone marrow have both direct and 
indirect antimicrobial properties which may vary between MSCs from different origins 
and could be exploited towards improvement of regenerative therapies for horses. 
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Introduction 
Equine mesenchymal stem/stromal cells (MSCs), obtained typically from bone 
marrow (BM) and adipose tissue (AT), have been used clinically for more than a 
decade. Although great progress has been made towards their characterisation [1-9], 
there is still a lack of understanding regarding their antibacterial and immune-related 
properties.  Antibiotic resistance is emerging as a major health risk for both humans 
and animals, and new strategies to ameliorate this problem are in great need.  
The regenerative potential of MSCs derives not only from their ability to 
differentiate into mature mesenchymal cell lineages, but also from a variety of 
immunomodulatory effects exerted by these cells [10-14] which, importantly, 
contribute to combating infection and determine clinical outcome in patients receiving 
MSCs. Moreover, human and mouse MSCs have been shown to express several 
antimicrobials and to be able to attenuate bacterial growth [12,15-17], a finding that 
has been recently extended to MSCs derived from equine blood [18].  
In humans, MSCs can have different inflammatory phenotypes depending on the 
extracellular milieu [19]. Interestingly, in a low inflammatory environment or upon 
activation of Toll-like receptor 4 (TLR4) by bacterial lipopolysaccharide (LPS), MSCs 
polarise to a pro-inflammatory state (MSC1), characterised by increased production of 
chemokines and cytokines that may recruit and activate immune effector cells [19]. In 
a different environment, MSCs may display an anti-inflammatory phenotype (MSC2). 
A limited number of studies have investigated the immunological properties of 
equine MSCs [4,20,21]. Moreover, there is accumulating evidence that MSCs from 
4 
 
different tissue sources differ in their TLR-expression profiles and response to 
inflammatory stimuli [22]. In this study, we investigated the antibacterial and 
immunomodulatory properties of MSCs from three different equine tissues sources, 
namely, BM and AT, the two most common sources of clinical MSCs, and endometrium 
(EM), a promising novel source of therapeutic MSCs [23,24]. 
 
Materials and Methods 
Sourcing of MSCs 
BM-, AT- and EM-MSCs were obtained each from 3 horses as described [5,23], and 
were characterised following the criteria established by the International Society for 
Cellular Therapy for MSCs [25]. All animal procedures were carried out according to 
the U.K. Home Office Animals (Scientific Procedures) Act 1986 with approval by the 
Ethical Review Committee, University of Edinburgh. BM-MSCs were obtained by 
aspiration of the sternum marrow, centrifugation on a density gradient, and culture of 
the resulting mononucleated cell layer. AT-MSCs were obtained by mincing 
subcutaneous adipose tissue followed by collagenase II (1 mg/ml; Gibco-Thermo 
Fisher Scientific, Paisley, UK)/BSA (3.5%) digestion at 37oC under agitation (100 rpm). 
Digestion was stopped by addition of DMEM 20% FBS (Gibco-Thermo Fisher Scientific), 
the fat layer removed and cells were further washed and seeded. To harvest EM-MSCs 
[23], the tissue was washed and minced and then dissociated in DMEM/F-12 
containing 0.1% bovine serum albumin (BSA), 0.5% collagenase I, 40 μg/ml 
deoxyribonuclease type I (Sigma Aldrich, Irvine, UK), and 1% penicillin/streptomycin 
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(P/S) for 40 minutes at 37 °C. Stromal cells were separated by negative selection of 
epithelial cells using Muc1-beads, filtered, washed and cultured. MSCs were expanded 
in DMEM 10% FBS and 1% P/S at 37°C in a humidified atmosphere containing 5% 
carbon dioxide. Alveolar macrophages were obtained via bronchoalveolar lavage from 
adult horses and cryopreserved as previously described [27]. Prior to use, cells were 
thawed and seeded in 24-well plastic plates (Nunc, Thermo Scientific) at 1 x 106 
cells/ml in complete medium (RPMI-1640 with GlutaMAX™-I Supplement; Invitrogen), 
penicillin/streptomycin (Invitrogen) and 20% heat-inactivated Horse Serum (Sigma 
Aldrich) and incubated overnight at 37 °C and 5% CO2. The following day non-adherent 
cells were removed, and medium was replaced.  
 
Bacterial growth  
Conditioned medium (CM; DMEM 10% FBS) was harvested from MSCs (BM, EM and 
AT; 70000 cells/well in 12-well plates) after culture for 16h at 37°C. CM was spun to 
remove cell debris and kept at -80°C. Escherichia coli ZAP198 was inoculated in BM-, 
EM- and AT-CM for 16h at 37°C, and colony forming units (cfu/ml) were obtained by 
serial dilutions in Luria-Bertani (LB) agar plates. Bacteria grown in DMEM 10% FBS and 
LB served as positive controls.  
 
Gene expression analyses 
Total RNA was extracted using Trizol’s protocol and was reversed transcribed using 
Superscript III (18080-044; Invitrogen-Thermo Fisher Scientific). Transcript levels were 
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quantified using a MX3005P qPCR system (Stratagene, CA, USA) with primers listed in 
Table 1 and SensiFAST SYBR Lo-ROX kit (Bioline). Data were analysed using Stratagene 
MxPro software and the mRNA levels were determined relative to a standard curve 
(generated from sample pools) that was run simultaneously.  Results were normalised 
to 18S rRNA and glyceraldehyde 3-phosphate dehydrogenase (GAPDH), and expressed 
as arbitrary units (AU). Reverse transcriptase-negative and no template control 
samples were included in each run as negative controls. For the measurement of CSF1-
R mRNA levels, cDNA from equine macrophages and keratinocytes [26] were included 
as positive and negative controls, respectively.  
 
LPS stimulation experiments 
MSCs at passage 4-6 were seeded at a density of 70 000 cells/well in 12-well plates 
(Nunc, Thermo Scientific). After 24 hours, the cell culture medium was removed and 
replaced with medium containing 0 or 0.1 µg/ml LPS (Sigma-Aldrich). After 16 hours of 
incubation, wells were washed with PBS and cells harvested into Trizol (Thermo Fisher 
Scientific), frozen and stored at -80°C prior to further analysis. Cell stimulation 
conditions, 0.1 µg/ml LPS for 16h, were chosen based on results from previous time-
course and  LPS dose-response trials (Supplementary Fig. 1).  
 
Immunocytochemistry (ICC) 
Cultured cells were washed with PBS and fixed with PFA for 15 minutes, and kept at 
4oC until use. Cells were permeabilized using methanol:acetone (1:1) followed by 
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incubation with protein blocking solution (Insight Biotechnology, UK). Cells were then 
incubated with primary antibodies against Lipocalin-2 (ab41105, Abcam, Cambridge, 
UK) or TLR4 (sc-12511, Santa Cruz Biotecnology, Paso Robles, CA, USA) for 16h at 4oC, 
and then with secondary antibodies (anti-rabbit and anti-goat IgG (10042, 11057; both 
from Invitrogen-Thermo Fisher Scientific) conjugated to the AF568 fluorochrome). The 
primary antibodies have been previously used to detect Lipocalin-2 and TLR4 in equine 
samples [18,27]. Samples were then mounted in fluoroshield with 4′,6-diamidino-2-
phenylindole (DAPI;F6057; Sigma, St Louis, MO, USA) and micrographs taken with a 
camera connected to a Zeiss Axiovert 25 microscope. The same settings were used for 
all pictures taken for each antibody. Cells incubated with secondary antibody only 
were used as negative controls. 
 
Enzyme-Linked Immunosorbent Assay (ELISA) 
MCP-1 concentrations in cell culture supernatants were analysed by ELISA (ELE-
MCP-1, Cambridge Bioscience, Cambridge, UK) accordingly to the manufacturer's 
protocol. In brief, samples and standards were added to a 96 well plate coated with 
anti-Equine MCP-1 antibody, and incubated for 2.5 hours at room temperature with 
gentle agitation. Samples were washed and incubated with biotinylated antibody for 
1h. Following addition of HRP-conjugated streptavidin and 3,3,5,5'-
tetramethylbenzidine subtract reagent, signal detection was performed at 450 nm. 
Equine MCP-1 protein provided in the kit was used to produce the standard curve.  
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Statistical analysis 
The effects of LPS on MSCs from different tissues were analysed by two-way ANOVA 
including "tissue", "treatment", "tissue x treatment" interaction and "animal" nested 
within "tissue" using the Minitab 17 statistical software (Minitab Inc.). Fisher's test was 
used for post-hoc comparisons.  Data were log-transformed before analyses to comply 
with normality criteria. Significance was set at p<0.05.  
 
 
Results 
Equine MSCs attenuate bacterial growth and express Lipocalin-2 
To assess direct effects of MSCs on bacterial growth, E. coli were inoculated in 
conditioned media (CM) from BM-, EM- and AT-MSCs. All three CM attenuated 
bacterial growth, although, on average, EM- and AT-MSC had more pronounced 
effects than BM-MSC media (Fig. 1A). We then determined whether equine MSCs 
expressed antimicrobial genes.  All cell types expressed Lipocalin-2, both at the mRNA 
(Fig. 1B) and protein (Fig. 1C) levels, but not other antimicrobial genes assayed, 
namely, LL-37 and β-defensin 1. Interestingly, EM-MSCs expressed Lipocalin-2 at 
higher mean levels (≥2-fold) than BM- and AT-MSCs (Fig. 1B). Moreover, fluorescence 
ICC showed increased Lipocalin-2 protein signal in MSCs stimulated with LPS (Fig. 1C). 
 
Equine MSCs express immunomodulatory genes 
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To examine the immunomodulatory properties of the three types of MSCs, we 
determined the expression of genes including the cytokines, Monocyte 
chemoattractant protein-1 (MCP-1), Chemokine ligand-5 (CCL5), Interleukin-6 (IL-6) 
and Interleukin-8 (IL-8). Samples had detectable levels of all cytokines analysed (Fig. 
2).  Mean MCP-1 mRNA levels were higher (≥2.9-fold) in BM- and EM- than in AT-MSCs 
(Fig. 2A). Similarly, CCL5 and IL-6 were expressed at relative much lower levels in AT-
MSCs (Fig. 2B,C), whereas mean IL-8 expression was much higher (≥7-fold) in EM- than 
in either BM- or AT-MSCs (Fig. 2D). Thus, AT-MSCs expressed the lowest levels of all 
immunomodulatory genes analysed. 
 
MSCs are responsive to LPS  
We then examined the effects of stimulation with LPS on the expression of 
immunomodulatory genes by MSCs. LPS induced a dramatic increase (≥7-fold; P<0.05) 
in MCP-1 mRNA levels across all three cell types (Fig. 3A). An increase in CCL5 mRNA 
was also observed although this was not significant for any cell type (Fig. 3B). In 
contrast, for both IL-6, a graded response to LPS was observed across cells with lower 
fold-induction in AT-MSCs (P<0.05) than in BM-MSCs (P<0.0001) or EM-MSCs 
(P<0.001; Fig. 3C,D). A similar graded response in IL-8 mRNA was observed with the 
LPS-induction being significant (P<0.05) only in BM-MSCs (P<0.05). To confirm the 
results from qPCR, we analysed MCP-1 levels in conditioned media using a commercial 
available ELISA kit that recognises the equine protein. In agreement with mRNA data 
(Fig. 3A), MCP-1 protein was significantly induced in response to LPS (Fig. 3E) in BM-
10 
 
MSCs (0.4±0.07 vs 1.4±0.3 ng/ml for unstimulated and LPS-stimulated, respectively, 
P<0.05), EM (0.2±0.03 vs 0.9±0.07, P<0.001) and AT (0.09±0.02 vs 0.3±0.02, P<0.05). 
We also quantified the relative expression of TLR4 [28], a cognate LPS receptor, in 
MSC preparations both at the mRNA (Fig. 4A) and protein (Fig. 4B) levels. TLR4 was 
detected in unstimulated cells, although at variable levels; mean mRNA levels were 
higher (≥6.5-fold) in BM- and EM-MSCs than in AT-MSC (Fig. 4A), consistent with 
protein data (upper row in Fig 4B). Cells were then stimulated with LPS for 16h. This 
did not produce any apparent changes in cell morphology or cell numbers (Fig. 4C), 
but results from fluorescence ICC indicated increased levels of TLR4 protein in 
response to LPS in all MSC types (Fig. 4B).   
 
Low levels of CSF1-R are present in BM- and EM-MSC preparations  
To assess whether contamination of MSCs with immune cells such as macrophages, 
as reported in other studies [29], may have influenced our results, we measured the 
expression of the macrophage-specific gene, colony stimulating factor 1 receptor 
(CSF1-R), in MSC preparations and compared these with the levels expressed by 
macrophages (positive control) and keratinocytes (negative control). CSF1-R was 
detected at very low levels in BM- and EM-MSCs (<700-fold lower than in macrophage 
samples) but not in AT-MSCs or keratinocytes. Although this finding did not completely 
rule out the presence of macrophages in MSC preparations, LPS stimulation did not 
induce changes in CSF1-R expression either (Fig. 5). 
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Discussion 
Antimicrobial resistance poses a growing threat for both Animal and Human Health, 
requiring the identification of novel approaches to fight microbial infection. Studies 
over the past 10 years have demonstrated the immunomodulatory nature of MSCs 
including direct antimicrobial effects [12,13,15,17,18,30-32], providing an attractive 
therapeutic tool alternative or complementary to the use of antibiotics. The 
identification of novel MSC sources has also represented a step forward in that regard. 
For example, while bone marrow and adipose are well established sources of clinical 
MSCs in both humans and animals, endometrium is now emerging as a promising 
alternative source with defined cell differentiation and immunomodulatory properties 
[23,24,30,33].  It is thus critical to compare the immunomodulatory properties of MSCs 
across different tissues to identify the most optimal source(s) for each particular 
clinical application. In that regard, this is to our knowledge the first study to 
simultaneously compare the properties of MSCs from bone marrow, endometrium 
and adipose.   
Several studies in humans and rodents [16,34] have shown that MSCs are able to 
attenuate microbial growth and that this effect can be attributed to the production of 
antimicrobials. These findings were recently extended for the first time to the horse, 
specifically to equine blood-derived MSCs [18]. Here, we report that several common 
sources of clinical MSCs in the horse are able to inhibit bacterial growth and that this 
effect varies between cell sources, being apparently higher for EM- and AT- than for 
BM-MSCs. Moreover, we show that all three cell sources express Lipocalin-2, and that 
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EM-MSCs express, on average, the highest levels. In agreement with our results, a 
recent study showed that production of lipocalin-2, among other antimicrobial 
peptides, contributed to the antibacterial effects of equine blood-derived MSCs, which 
did not produce β-defensin [18].  In contrast to our results, however, blood-derived 
MSCs did produce substantial LL-37, a finding which may reflect tissue-specific 
differences in antimicrobial production by MSCs. In that regard, human BM- and 
umbilical cord blood (UCB)-MSCs have been shown to reduce bacterial growth through 
the secretion of LL-37 and β-defensin 2, respectively [15,16,34]. Our observation of 
apparent highest lipocalin-2 expression in EM-MSCs may be linked to the fact that, 
unlike BM or AT, EM provides a natural body barrier against infection. EM-MSCs could 
thus provide distinct benefits for clinical use. 
In addition to lipocalin-2, equine MSCs from all sources examined expressed the 
immunomodulatory genes, MCP-1, IL-6, IL-8 and CCL5, suggesting theses cytokines 
may contribute to the reported ability of equine MSCs to limit infection indirectly via 
recruiting and activating immune cells [32,35]. Of these four cytokines, MCP-1 and 
CCL5 have to our knowledge not been reported previously to be expressed in equine 
MSCs. Of interest, expression of all of the above immunomodulatory genes was 
generally reduced in AT- relative to BM- and EM-MSCs. Although we don’t have an 
explanation for this, expression of CSF1-R was lowest in AT-MSCs suggesting that 
contamination by macrophages, even at low levels, may have possibly contributed to 
the elevated cytokine expression in BM and EM. Indeed, the presence of 
contaminating leukocyte populations in MSC preparations likely contributes to the 
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variability in clinical outcomes reported with the use of these cells. On the other hand, 
it has also been reported that BM mesenchymal progenitor cells can originate from 
CD14+ cells [36]. Overall, this highlights the need for more robust characterisation of 
MSC populations. 
In the context of infection and tissue repair, the inflammatory microenvironment 
and specific pattern of TLR expression in effector cells determine both the interactions 
between MSCs and immune cells as well as the outcome of tissue regeneration 
approaches using MSCs [37]. In agreement with findings with human BM- and AT-
MSCs [38], and equine UCB-MSCs [20], we detected expression of TLR4 in MSCs from 
all sources, consistent with their responsiveness to LPS. Polarisation into a pro-
inflammatory MSC1-phenotype in response to TLR4 activation is marked by increased 
secretion of immune effector-recruiting cytokines and chemokines [19]. In this study, 
in general, the expression of MCP-1, IL-6, IL-8 and CCL5 increased in response to LPS-
stimulation, consistent with reports with human AT- and BM-MSCs [39,40] and, for 
those cytokines that have been examined (IL-6 and IL-8), equine BM-MSCs [41].   
In summary, our results suggest that MSCs from different sources have both 
antimicrobial activity and constitutively produce Lipocalin-2, which may 
physiologically contribute to innate immune responses, particularly in the case of EM-
MSCs. However, the largest component of the reported in vivo antibacterial activity of 
MSCs is likely to involve indirect activation of immune effector cells. This conclusion is 
in line with observations that LPS-stimulated human MSCs induce both the expression 
of IL-6 and IL-8 and enhance activation and phagocytic activity of polymorphonuclear 
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neutrophils [42].  Overall our findings suggest that equine MSCs, particularly EM-MSCs, 
could be of benefit for reducing and limiting infection. However, further studies will 
be necessary to assess the antibacterial activity of these cells in an in vivo context so 
new strategies can be developed to diversify their use and increase their therapeutic 
efficiency.  
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 Figure legends 
Fig. 1. A) E. coli growth, indicated as cfu/ml, 16h after bacteria inoculation in 
conditioned media from bone marrow (BM)-, endometrium (EM)- or adipose tissue 
(AT)-MSCs or in growth medium only (positive control, C). B) Lipocalin-2 transcript 
levels in equine MSCs from BM, EM or AT. Data are shown as Mean + SEM (n=3 
horses/tissue type). Mean mRNA levels in BM-MSC samples were set to 1. AU, 
arbitrary units. C) Fluorescence ICC of unstimulated (Uns) or LPS-stimulated MSCs from 
BM, EM, or AT, with Lipocalin-2 antibody. Negative controls (-ve) were produced with 
LPS-stimulated cells incubated with secondary antibody only, and positive control 
(+ve) resulted from staining of alveolar macrophages with Lipocalin-2 antibody. 
Lipocalin-2 is indicated by red signal and DAPI-stained nuclei is shown by blue. Pictures 
were taken in an Axiovert 25 Inverted Microscope. Scale bars, 100 µm.  
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Fig. 2. Transcript levels of A) MCP-1, B) CCL5, C) IL-6 and D) IL-8 in MSCs from bone 
marrow (BM), endometrium (EM) and adipose tissue (AT). Data are shown as Mean + 
SEM (n=3 horses/tissue type). Mean mRNA levels of BM-MSC samples was set to 1. 
AU, arbitrary units.  
 
Fig. 3. Fold-change in MCP-1 (A), CCL5 (B), IL-6 (C) and IL-8 (D) mRNA levels, and MCP-
1 protein levels (E) after LPS stimulation (grey bars) of MSCs from bone marrow (BM), 
endometrium (EM) and adipose tissue (AT). In each case, data (shown as Mean + SEM; 
n=3 horses/tissue type) were normalized to mean mRNA levels in unstimulated cells 
(black bars). * (p<0.05), ** (p<0.001) and *** (p<0.0001) indicate differences between 
unstimulated and stimulated cells, while different superscripts (a, b) show significant 
differences between cell types (p<0.03). 
 
Fig. 4. A) TLR4 expression measured by qPCR in unstimulated MSCs from bone marrow 
(BM), endometrium (EM) and adipose tissue (AT). Data are shown as Mean + SEM (n=3 
horses/tissue type). Mean mRNA levels in BM-MSC samples were set to 1. AU, 
arbitrary units. B, C) Photomicrographs showing (B) fluorescence immunostaining of 
TLR4 (in red) and (C) bright field images of MSCs from bone marrow (BM), 
endometrium (EM) and adipose tissue (AT) before (unstimulated, Uns) and after a 16h-
simulation with LPS (0.1 µg/ml). Negative controls (-ve) correspond to LPS-stimulated 
cells incubated with secondary antibody only, and positive control (+ve) to alveolar 
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macrophages incubated with TLR4 antibody. All pictures were taken in an Axiovert 25 
Inverted Microscope. Scale bars, 100 µm. 
 
Fig. 5. mRNA levels of the macrophage marker, CSF1-R, in unstimulated (Uns) and LPS-
stimulated (0.1 µg/ml LPS for 16h) MSCs from equine bone marrow (BM), 
endometrium (EM) and adipose tissue (AT). Keratinocyte (K) and macrophage (M) 
samples were used as negative and positive controls, respectively. Results are shown 
as Mean + SEM. N=3 horses/tissue type. NB, not detected; AU, arbitrary units. 
 
Supplementary Fig. 1. IL-6 mRNA levels from BM- (A) and AT-MSCs (B) that were 
unstimulated (Uns) or stimulated with 0.1 or 1 µg/ml LPS for 8 or 24h. Results (Mean 
+ SEM) are from one cell preparation of each type assayed in triplicate. AU, arbitrary 
units. 
 
 
Table 1. Gene and respective pair of primers used for qPCR. 
Gene Sense primer sequence (5’-3’)   Antisense primer sequence (5’-3’) Reference 
IL-6 GGACCACTACTCACCACTGC CCCAGATTGGAAGCATCCGT  
MCP-1 ATATCAGGGGGCATTTAGGG      ATTGGCCAAGGAGATCTGTG  
CCL5 CAGTCGTCTTTGTCACCCGA GGTTCGAGATGCCCTCCAAT  
LCN2 CCACAGCTACAACGTCACCT GGCTGGGAACTTGGGATGAA  
IL-8 CTTTCTGCAGCTCTGTGTGAAG GCAGACCTCAGCTCCGTTGAC (39) 
TLR-4 GCCACCTGTCAGATTAGCAAGA AGAACTGCTATGACAGAAACCATGA (28) 
CSF-1R GAAATACGTCCGCAGGGACA GACACGGGTCTCATCTCCAC  
IDO ACAACATCAGGACCAGGACAC  CCAGACGCCTTCATAGAG (4) 
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TNFα CCTGTAGCCCATGTTGTAGCA GGACCTGGGAGTAGATGAGGT  
18S GCTGGCACCAGACTTG GGGGAATCAGGGTTCG  
GAPDH CAGAACATCATCCCTGCTTC           ATGCCTGCTTCACCACAATTC  
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